Description
Introduction:
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. FDA approved the same as & ldquo;Firmagon& rdquo; in December 2008.
Intended Use:
The KRIBIOLISA Degarelix (Firmagon) ELISA is used to estimate the level of Degarelix in human serum and plasma. The kit is intended for research use only.
Principle:
The ELISA is a competitive immunoassay for the determination of Degarelix. A constant concentration of Degarelix coated on the microplate and varying concentration of standard or sample will compete for binding to gonadotropin-releasing hormone (GnRH) receptor. Detection antibody against GnRH conjugated to HRP is added to form a complex. The complex will produce a soluble colored product on substrate addition. The enzyme reaction is stopped by dispensing of Stop Solution into the wells. The optical density (OD) of the solution at 450 nm is inversely proportional to the amount of bound Degarelix present in standards or samples.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!